Twin Tree Management
CRSP icon

Twin Tree Management’s CRISPR Therapeutics CRSP Stock Holding History

Twin Tree Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,100
Closed -$329K – 1327
2022
Q4 		$329K Hold
8,100
– – ﹤0.01% 1135
2022
Q3 		$529K Buy
+8,100
New +$587K ﹤0.01% 1120

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Twin Tree Management's CRSP Position: Q1 2024 in Review

Twin Tree Management sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 39,772 shares — an estimated $2.49M sold.

Twin Tree Management first reported a position in CRSP in Q3 2022 and held it in 3 quarters. The position peaked at $8.33M in Q3 2022. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Twin Tree Management reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Twin Tree Management sold 39,772 CRISPR Therapeutics shares in Q1 2024, an estimated $2.49M.
  • Twin Tree Management first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 3 quarters.
  • Twin Tree Management's CRISPR Therapeutics position peaked at $8.33M in Q3 2022.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Twin Tree Management's 13F filing for Q1 2024, filed 9 May 2024.